Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study

BACKGROUND: The combination of BRAF and MEK inhibitors has become standard of care in the treatment of metastatic BRAF V600-mutated melanoma. Clinical factors for an early prediction of tumor response are rare. The present study investigated the association between the development of an early exanth...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Front Oncol
Prif Awduron: Kähler, Katharina C., Gutzmer, Ralf, Meier, Friedegrund, Zimmer, Lisa, Heppt, Markus, Gesierich, Anja, Thoms, Kai-Martin, Utikal, Jochen, Hassel, Jessica C., Loquai, Carmen, Pföhler, Claudia, Heinzerling, Lucie, Kaatz, Martin, Göppner, Daniela, Pflugfelder, Annette, Bohne, Ann-Sophie, Satzger, Imke, Reinhardt, Lydia, Placke, Jan-Malte, Schadendorf, Dirk, Ugurel, Selma
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Frontiers Media S.A. 2021
Pynciau:
Oncology
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8183381/
https://ncbi.nlm.nih.gov/pubmed/34109122
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.672172
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg